Science Daily December 22, 2021 An international team of researchers (USA – University of Chicago, The Scripps Research Institute, La Jolla, CA, Icahn School of Medicine at Mount Sinai, New York, Fred Hutchinson Cancer Research Center, Seattle, WA, University of Washington, University of Maryland, Austria) has found a distinct class of broadly neutralizing antibodies (bnAbs) targeting a discrete membrane-proximal anchor epitope of the hemagglutinin (HA) stalk domain. The antibodies are broadly neutralizing across H1 viruses and can cross-react with pandemic-threat H2 and H5 viruses. Anchor epitope-targeting B cells are common in the human memory B cell (MBC) repertoire and were […]
Tag Archives: Vaccine
Licensing Opportunity: Virus-Like Particle Technology for Universal Flu Vaccine
Global Biodefense July 13, 2021 The National Institutes of Health (NIH) has a Technology Transfer opportunity available for a virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes. The technology has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes, further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine…read […]